Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

v3.25.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Total
Ordinary shares
Reserves
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Total Stockholders' Equity (Virax)
Non Controlling Interest
Number of shares, beginning balance at Mar. 31, 2022   997,655          
Equity, beginning balance at Mar. 31, 2022 $ (1,196,709) $ 998 $ 5,363,188 $ (6,336,966) $ (1,799) $ (974,579) $ (222,130)
Shares issued for cash, shares   425,750          
Shares issued for cash 13,654,215 $ 426 13,653,789     13,654,215  
Shares issued for services, shares   755          
Shares issued for services 20,000 $ 1 19,999     20,000  
Shares issued for settlement of related party payable, shares   5,430          
Shares issued for settlement of related party payable 39,864 $ 6 39,858     39,864  
Contributed capital - settlement of related party debt 109,570   109,570     109,570  
Cashless warrant exercise, shares   8,619          
Cashless warrant exercise 9 $ 9       9  
Pre-funded warrant exercise, shares   116,500          
Pre-funded warrant exercise 117 $ 117       117  
Stock-based compensation 1,734,601   1,734,601     1,734,601  
Foreign currency adjustment 111       111 111  
Net Loss (5,457,763)     (5,457,494)   (5,457,494) (269)
Number of shares, ending balance at Mar. 31, 2023   1,554,709          
Equity, ending balance at Mar. 31, 2023 8,904,015 $ 1,557 20,921,005 (11,794,460) (1,688) 9,126,414 (222,399)
Pre-funded warrant exercise, shares   234,331          
Pre-funded warrant exercise 234 $ 234       234  
Warrant exercise, shares   734,073          
Warrant exercise 1,872,506 $ 734 1,871,772     1,872,506  
Shares issued for settlement of debt, shares   22,500          
Shares issued for settlement of debt 85,500 $ 21 85,479     85,500  
Shares issued for rounding on Share Consolidation, shares   28,290          
Shares issued for rounding on Share Consolidation 28 $ 28       28  
Stock-based compensation 1,011,973   1,011,973     1,011,973  
Foreign currency adjustment 3,639       3,639 3,639  
Net Loss $ (6,739,120)     (6,733,537)   (6,733,537) (5,583)
Number of shares, ending balance at Mar. 31, 2024 2,573,903 2,573,903          
Equity, ending balance at Mar. 31, 2024 $ 5,138,775 $ 2,574 23,890,229 (18,527,997) 1,951 5,366,757 (227,982)
Shares issued for cash, shares   1,499,909          
Shares issued for cash 5,128,186 $ 1,500 5,126,686     5,128,186  
Warrant exercise, shares   268,144          
Warrant exercise 786,736 $ 268 786,468     786,736  
Stock-based compensation 365,309   365,309     365,309  
Foreign currency adjustment 110,379       110,379 110,379  
Net Loss $ (6,067,232)     (6,061,247)   (6,061,247) (5,985)
Number of shares, ending balance at Mar. 31, 2025 4,341,956 4,341,956          
Equity, ending balance at Mar. 31, 2025 $ 5,462,153 $ 4,342 $ 30,168,692 $ (24,589,244) $ 112,330 $ 5,696,120 $ (233,967)